|Mr. Anthony A. DiTonno||CEO & Director||389.21k||N/A||1948|
|Mr. Michael B. Jebsen||Pres & CFO||680.81k||N/A||1971|
|Ms. Nancy J. M. Hecox||Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Maria Isabel Tomargo||Assistant VP of Marketing & Sales||N/A||N/A||N/A|
|Mr. Robert F. Diegelmann||Head of New Wound Care Division||N/A||N/A||N/A|
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Tenax Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.